{"id":5244,"date":"2019-06-11T15:11:45","date_gmt":"2019-06-11T09:41:45","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5244"},"modified":"2021-07-24T12:57:24","modified_gmt":"2021-07-24T07:27:24","slug":"notizia-tirzepatide","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide","title":{"rendered":"Notizia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a14686237dd1\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a14686237dd1\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide\/#Lilly_tests_the_efficacy_of_Tirzepatide-a_novel_dual_GIP_GLP-1_agonist\" >Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide\/#FDA_approves_Genentechs_Polivy_for_patients_with_relapsed_or_refractory_diffuse_large_B-cell_lymphoma\" >FDA approves Genentech&#8217;s Polivy for patients with relapsed or refractory diffuse large B-cell lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide\/#Blood_Markers_may_help_to_predict_Seizures_before_they_happen\" >Blood Markers may help to predict Seizures before they happen<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide\/#Pneumonia-causing_bacteria_mapped_in_a_genomic_survey\" >Pneumonia-causing bacteria mapped in a genomic survey<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lilly_tests_the_efficacy_of_Tirzepatide-a_novel_dual_GIP_GLP-1_agonist\"><\/span><strong>Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly controlled Type 2 diabetes. Weight reduction has shown a positive effect in lowering NASH. Moreover, improvement of insulin sensitivity and lipid and fat metabolism can successfully improve NASH. The trials revealed that a higher dose in Tirzepatide lowers down the risk of liver disease at great extent. At present,<strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-alcoholic-steatohepatitis-nash-pipeline-insight\">NASH therapy market<\/a> <\/strong>constitutes three drugs, namely Obeticholicacid (OCA) Emricasan and Selonsertib. Tirzepatide can be a new drug which has the potential to improve NASH patient pool. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_approves_Genentechs_Polivy_for_patients_with_relapsed_or_refractory_diffuse_large_B-cell_lymphoma\"><\/span><strong>FDA approves Genentech&#8217;s Polivy for patients with relapsed or refractory diffuse large B-cell lymphoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>FDA, today, granted accelerated approval to Polivy (Polatuzumab vedotin-piiq)\u00a0in combination with the chemotherapy bendamustine and a rituximab product to treat adult patients with diffuse large B-cell lymphoma who have received at least two prior therapies. Polivy\u00a0is an antibody-drug conjugate that targets a protein expressed in the majority of B cells, known as <strong>CD79b<\/strong>, which are affected by certain kinds of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/non-hodgkins-lymphoma-nhl-market\">non-Hodgkin lymphoma<\/a><\/strong>.\u00a0Polivy\u00a0has already been granted\u00a0Breakthrough Therapy\u00a0and\u00a0Priority Review designations along with\u00a0Orphan Drug designation. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Blood_Markers_may_help_to_predict_Seizures_before_they_happen\"><\/span><strong>Blood Markers may help to predict Seizures before they happen <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Researchers at FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, hosted at RCSI (Royal College of Surgeons in Ireland)\u00a0discovered a formation of certain pattern of molecules that appear in blood before a seizure happens in people living with <strong>Epilepsy<\/strong>. At present, the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-pipeline-insight\">Epilepsy therapy market<\/a><\/strong> is dominated by several Antiepileptic Drugs (AEDs) like GABA Enhancers\/ Inhibitors, Ca Channel Blockers, Na Channel Blockers, etc. However, Epidiolex is the only approved therapy in Epilepsy therapeutic market. The discovery of certain changes in the blood due to the fragments of transfer RNAs (tRNAs), will help patients deal with the most difficult aspect of Epilepsy- unpredictable occurrence of seizures. \u00a0 <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pneumonia-causing_bacteria_mapped_in_a_genomic_survey\"><\/span><strong>Pneumonia-causing bacteria mapped in a genomic survey  <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Research published in <em>The Lancet Infectious Diseases <\/em>mapped the most common bacterial cause of pneumonia around the world. \u00a0The research revealed the most prevalent strains of <em>Streptococcus pneumonia <\/em>discovering 621 strains. <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pneumonia-pneumococcal-market\">Pneumonia <\/a><\/strong>is an infection of the lungs that is responsible for the deaths of hundreds of thousands of people a year globally and is the single largest infectious cause of death of children under 5 years old worldwide. The pneumococcus can cause disease in other areas of the body too, for example infecting the brain or blood, causing meningitis or bloodstream infections, which can all lead to sepsis. The use of the <strong>pneumococcal conjugate vaccine <\/strong>(PCV) for the past ten years has helped in reducing a number of childhood infections, but even then these vaccines are effective against a few coat types. The identification of new strains will help in advancing vaccine use against Pneumonia. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly controlled Type 2 diabetes. Weight reduction has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5245,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[102,2139,228,1494,2985,704,1135,667,1469,4502],"industry":[17225],"therapeutic_areas":[17239,17245,17228],"class_list":["post-5244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-b-cell-malignancies","tag-diabetes-mellitus","tag-eli-lilly","tag-epilepsy","tag-epilepsyseizures","tag-fda","tag-genentech","tag-lymphoma","tag-nash","tag-pneumonia","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 11\/06\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide,also known as LY3298176...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 11\/06\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide,also known as LY3298176...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-11T09:41:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09182208\/Notizia-11-june.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 11\/06\/2019 - DelveInsight Business Research","description":"Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide,also known as LY3298176...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide","og_locale":"en_US","og_type":"article","og_title":"Notizia 11\/06\/2019 - DelveInsight Business Research","og_description":"Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide,also known as LY3298176...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-11T09:41:45+00:00","article_modified_time":"2021-07-24T07:27:24+00:00","og_image":[{"width":750,"height":410,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09182208\/Notizia-11-june.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide","url":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide","name":"Notizia 11\/06\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09182208\/Notizia-11-june.png","datePublished":"2019-06-11T09:41:45+00:00","dateModified":"2021-07-24T07:27:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide,also known as LY3298176...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-tirzepatide#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09182208\/Notizia-11-june.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09182208\/Notizia-11-june.png","width":750,"height":410,"caption":"Notizia 11 june"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09182208\/Notizia-11-june-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">B-cell malignancies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">diabetes mellitus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epilepsy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">EpilepsySeizures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pneumonia<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">B-cell malignancies<\/span>","<span class=\"advgb-post-tax-term\">diabetes mellitus<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy<\/span>","<span class=\"advgb-post-tax-term\">EpilepsySeizures<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">lymphoma<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">pneumonia<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 11, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 11, 2019 3:11 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5244"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5244\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5245"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5244"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5244"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}